{"count": 11, "results": [{"_id": "15311110", "pmid": 15311110, "title": "Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.", "journal": "J Hypertens", "authors": ["Ibsen H", "Wachtell K", "Olsen MH", "Borch-Johnsen K", "Lindholm LH", "Mogensen CE", "Dahlöf B", "Devereux RB", "de Faire U", "Fyhrquist F", "Julius S", "Kjeldsen SE", "Lederballe-Pedersen O", "Nieminen MS", "Omvik P", "Oparil S", "Wan Y", "LIFE substudy"], "date": "2004-09-01T00:00:00Z", "doi": "10.1097/00004872-200409000-00026", "meta_date_publication": "2004 Sep", "meta_volume": "22", "meta_issue": "9", "meta_pages": "1805-11", "score": 50069.156, "text_hl": "Reduction in @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ explained one-fifth of the benefits of @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ versus @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@.", "citations": {"NLM": "Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y, LIFE substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens. 2004 Sep;22(9):1805-11. PMID: 15311110", "BibTeX": "@article{15311110, title={Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.}, author={Ibsen H and Wachtell K and Olsen MH and Borch-Johnsen K and Lindholm LH and Mogensen CE and Dahlöf B and Devereux RB and de Faire U and Fyhrquist F and Julius S and Kjeldsen SE and Lederballe-Pedersen O and Nieminen MS and Omvik P and Oparil S and Wan Y and LIFE substudy}, journal={J Hypertens}, volume={22}, number={9}, pages={1805-11}}"}}, {"_id": "7926346", "pmid": 7926346, "title": "Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.", "journal": "Diabetologia", "authors": ["Elving LD", "Wetzels JF", "van Lier HJ", "de Nobel E", "Berden JH"], "date": "1994-06-01T00:00:00Z", "doi": "10.1007/BF00403380", "meta_date_publication": "1994 Jun", "meta_volume": "37", "meta_issue": "6", "meta_pages": "604-9", "score": 50064.684, "text_hl": "With @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ decreased from 933 (603-1445) to 676 (437-1047) mg/24 h and @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ from 1.5 (1.0-2.4) to 0.9 (0.6-1.5) g/24 h.", "citations": {"NLM": "Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. Diabetologia. 1994 Jun;37(6):604-9. PMID: 7926346", "BibTeX": "@article{7926346, title={Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.}, author={Elving LD and Wetzels JF and van Lier HJ and de Nobel E and Berden JH}, journal={Diabetologia}, volume={37}, number={6}, pages={604-9}}"}}, {"_id": "8070610", "pmid": 8070610, "title": "Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.", "journal": "Diabetes", "authors": ["Nielsen FS", "Rossing P", "Gall MA", "Skøtt P", "Smidt UM", "Parving HH"], "date": "1994-09-01T00:00:00Z", "doi": "10.2337/diab.43.9.1108", "meta_date_publication": "1994 Sep", "meta_volume": "43", "meta_issue": "9", "meta_pages": "1108-13", "score": 50060.37, "text_hl": "@<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@Albuminuria@@@ was on average reduced 45% in the @CHEMICAL_Lisinopril @CHEMICAL_MESH:D017706 @@@lisinopril@@@ group vs. 12% in the @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ group (P < 0.01), and fractional albumin clearance was on average reduced 49% in the @CHEMICAL_Lisinopril @CHEMICAL_MESH:D017706 @@@lisinopril@@@ group vs. 1% in the @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ group (P < 0.05). ", "citations": {"NLM": "Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1994 Sep;43(9):1108-13. PMID: 8070610", "BibTeX": "@article{8070610, title={Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.}, author={Nielsen FS and Rossing P and Gall MA and Skøtt P and Smidt UM and Parving HH}, journal={Diabetes}, volume={43}, number={9}, pages={1108-13}}"}}, {"_id": "18651547", "pmid": 18651547, "title": "Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.", "journal": "J Nephrol", "authors": ["Ibsen H", "Olsen MH", "Wachtell K", "Borch-Johnsen K", "Lindholm LH", "Mogensen CE"], "date": "2008-07-01T00:00:00Z", "meta_date_publication": "2008 Jul-Aug", "meta_volume": "21", "meta_issue": "4", "meta_pages": "566-9", "score": 50059.547, "text_hl": "In the LIFE-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ subgroup we found that reduction in @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ was more pronounced in @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@-based as compared with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@-based treatment. ", "citations": {"NLM": "Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol. 2008 Jul-Aug;21(4):566-9. PMID: 18651547", "BibTeX": "@article{18651547, title={Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.}, author={Ibsen H and Olsen MH and Wachtell K and Borch-Johnsen K and Lindholm LH and Mogensen CE}, journal={J Nephrol}, volume={21}, number={4}, pages={566-9}}"}}, {"_id": "1310913", "pmid": 1310913, "title": "Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.", "journal": "Clin Sci (Lond)", "authors": ["Stornello M", "Valvo EV", "Scapellato L"], "date": "1992-01-01T00:00:00Z", "doi": "10.1042/cs0820019", "meta_date_publication": "1992 Jan", "meta_volume": "82", "meta_issue": "1", "meta_pages": "19-23", "score": 50056.96, "text_hl": "These data suggest that the inhibition of tissue angiotensin formation and the consequent reduction in glomerular permeability, rather than changes in renal and systemic haemodynamics, are the common mechanisms by which both @CHEMICAL_Enalapril @CHEMICAL_MESH:D004656 @@@enalapril@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ decreased @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ in our @SPECIES_9606 @@@patients@@@.", "citations": {"NLM": "Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers. Clin Sci (Lond). 1992 Jan;82(1):19-23. PMID: 1310913", "BibTeX": "@article{1310913, title={Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.}, author={Stornello M and Valvo EV and Scapellato L}, journal={Clin Sci (Lond)}, volume={82}, number={1}, pages={19-23}}"}}, {"_id": "12071084", "pmid": 12071084, "title": "[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].", "journal": "Praxis (Bern 1994)", "authors": ["Faller J", "Hess B"], "date": "2002-05-08T00:00:00Z", "doi": "10.1024/0369-8394.91.19.836", "meta_date_publication": "2002 May 8", "meta_volume": "91", "meta_issue": "19", "meta_pages": "836-44", "score": 50048.58, "text_hl": "This has lately been confirmed by a prospective trial in comparison to the betablocker @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. Based on these data, demographics of the Swiss population, literature data on mortality rates of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetics@@@ with @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@impaired renal function@@@ and studies on true costs of antihypertensives, we calculated the costs of a longterm intervention (20 years) with antihypertensives in 3536 middle-aged Swiss @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ and @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@macro-albuminuria@@@ whose antihypertensive regimen was based either on the ACEI @CHEMICAL_Lisinopril @CHEMICAL_MESH:D017706 @@@lisinopril@@@, or the ND-HP-CCB @CHEMICAL_Verapamil @CHEMICAL_MESH:D014700 @@@verapamil@@@, or the betablocker @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Faller J, Hess B. [Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care]. Praxis (Bern 1994). 2002 May 8;91(19):836-44. PMID: 12071084", "BibTeX": "@article{12071084, title={[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].}, author={Faller J and Hess B}, journal={Praxis (Bern 1994)}, volume={91}, number={19}, pages={836-44}}"}}, {"_id": "9732338", "pmid": 9732338, "title": "Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.", "journal": "BMJ", "authors": ["UK Prospective Diabetes Study Group"], "date": "1998-09-12T00:00:00Z", "meta_date_publication": "1998 Sep 12", "meta_volume": "317", "meta_issue": "7160", "meta_pages": "713-20", "score": 50048.156, "text_hl": "Similar proportions of @SPECIES_9606 @@@patients@@@ in the two groups showed deterioration in @DISEASE_Hypertensive_Retinopathy @DISEASE_MESH:D058437 @@@retinopathy@@@ by two grades after nine years (31% in the @CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@ group and 37% in the @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ group) and developed clinical grade @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ >=300 mg/l (5% and 9%). ", "citations": {"NLM": "UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):713-20. PMID: 9732338", "BibTeX": "@article{9732338, title={Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.}, author={UK Prospective Diabetes Study Group}, journal={BMJ}, volume={317}, number={7160}, pages={713-20}}"}}, {"_id": "18370544", "pmid": 18370544, "title": "Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.", "journal": "Clin Drug Investig", "authors": ["Seedat YK", "Randeree IG"], "date": "1998-01-01T00:00:00Z", "doi": "10.2165/00044011-199816030-00007", "meta_date_publication": "1998", "meta_volume": "16", "meta_issue": "3", "meta_pages": "229-40", "score": 50047.227, "text_hl": "INTERVENTIONS: The study drugs were @CHEMICAL_Perindopril @CHEMICAL_MESH:D020913 @@@perindopril@@@ 4 to 8mg once daily or @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ 50 to 100mg once daily. ", "citations": {"NLM": "Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40. PMID: 18370544", "BibTeX": "@article{18370544, title={Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.}, author={Seedat YK and Randeree IG}, journal={Clin Drug Investig}, volume={16}, number={3}, pages={229-40}}"}}, {"_id": "15089793", "pmid": 15089793, "title": "The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.", "journal": "Diabet Med", "authors": ["Rachmani R", "Slavachevsky I", "Amit M", "Levi Z", "Kedar Y", "Berla M", "Ravid M"], "date": "2004-05-01T00:00:00Z", "doi": "10.1111/j.1464-5491.2004.01194.x", "meta_date_publication": "2004 May", "meta_volume": "21", "meta_issue": "5", "meta_pages": "471-5", "score": 50046.14, "text_hl": "@SPECIES_9606 @@@PATIENTS@@@ AND METHODS: Sixty female @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@ aged 45-70 years with blood pressure (BP) 140-180/90-110 mmHg, serum @CHEMICAL_Creatinine @CHEMICAL_MESH:D003404 @@@creatinine@@@ (sCr) < or = 160 micro mol/l, HbA(1c) < or = 10%, and @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ were treated by @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ 12.5-75 mg/d and @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@hydrochlorothiazide@@@ 6.25-25 mg/d. ", "citations": {"NLM": "Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2004 May;21(5):471-5. PMID: 15089793", "BibTeX": "@article{15089793, title={The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.}, author={Rachmani R and Slavachevsky I and Amit M and Levi Z and Kedar Y and Berla M and Ravid M}, journal={Diabet Med}, volume={21}, number={5}, pages={471-5}}"}}, {"_id": "1857482", "pmid": 1857482, "title": "Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.", "journal": "Nephron", "authors": ["Stornello M", "Valvo EV", "Scapellato L"], "date": "1991-01-01T00:00:00Z", "doi": "10.1159/000186378", "meta_date_publication": "1991", "meta_volume": "58", "meta_issue": "1", "meta_pages": "52-7", "score": 50045.75, "text_hl": "According to these results we can hypothesize that the inhibition of tissue angiotensin formation and its related change on the glomerular permeability, rather than renal and systemic hemodynamic features, seem to be the common mechanisms by which both @CHEMICAL_Enalapril @CHEMICAL_MESH:D004656 @@@enalapril@@@ as well as @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ decrease the @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ in our @SPECIES_9606 @@@patients@@@.", "citations": {"NLM": "Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron. 1991;58(1):52-7. PMID: 1857482", "BibTeX": "@article{1857482, title={Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.}, author={Stornello M and Valvo EV and Scapellato L}, journal={Nephron}, volume={58}, number={1}, pages={52-7}}"}}]}